Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Prospective Study of Camrelizumab Combined With Apatinib, Etoposide and Cisplatin in First-line Treatment of Extensive Small-cell Lung Cancer.

NCT04490421 is registered in ClinicalTrials.gov with Fuzhou General Hospital as lead sponsor.

NCT NCT04490421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04490421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Prospective Study of Camrelizumab Combined With Apatinib, Etoposide and Cisplatin in First-line Treatment of Extensive Small-cell Lung Cancer.
Lead sponsor
Fuzhou General Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
August 1, 2020
Completion date
February 1, 2022
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasm, pd-1 inhibitors, small cell lung cancer